Ana Olivia Laurentino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Olivia Laurentino has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bruna Haendchen Sant'ANa
Programa de Pós-graduação em Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
2 shared publications - Mirna Bainy Leal
Programa de Pós-graduação em Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Programa de Pós-graduação em Neurociências, UFRGS, Porto Alegre, Brazil
2 shared publications - Rosane Gomez
Programa de Pós-graduação em Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
2 shared publications - Bruno Ayala Vidal
Programa de Pós-Graduação em Farmacologia e Terapêutica (PPGFT), Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2600\432, Porto Alegre, Rio Grande do Sul, 90035-003, Brazil
1 shared publication - Bruno Dutra Arbo
Departamento de Farmacologia, Instituto de Ciências Básicas e da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcellos, 2600, Porto Alegre 90035-003, RS, Brazil
1 shared publication - Douglas Marques
Programa de Pós‐Graduação em Ciências Biológicas: Neurociências, Instituto de Ciências Básicas da Saúde Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre Brazil
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Taurine reduces intracellular glucose accumulation in fructose-treated Caenorhabditis elegans
Regulation of glucose homeostasis is a central feature of antidiabetic drugs such as metformin. However, a subset of individuals exhibited limited therapeutic response, highlighting the need for complementary treatment strategies. Taurine, a semi-essential amino acid, has been reported to improve glycemic control in mammalian models, supporting its potential as an adjuvant therapy for metabolic disorders. In this study, we established a fructose-induced metabolic dysfunction model in Caenorhabditis elegans (C. elegans), characterized by increased intracellular glucose accumulation, and evaluated the effects of taurine. A metabolic dysfunction state was induced in L1-stage N2 Bristol worms by exposing them to 500 mM fructose for 48 h. Metformin (25, 50, and 100 µM) was initially used to establish an effective pharmacological control, and the optimal dose (50 µM) was subsequently employed as a positive control to assess the effects of taurine (10, 50, and 100 µM) under fructose-induced conditions. Fructose exposure significantly increased intracellular glucose levels. Metformin reduced intracellular glucose at all concentrations tested and improved survival at the lowest dose, without affecting morphological parameters. Taurine reduced intracellular glucose accumulation only at the highest concentration tested (100 µM), whereas lower concentrations selectively increased survival, indicating dose-dependent and functionally distinct effects on glucose regulation and organismal viability. These findings show that taurine modulates intracellular glucose accumulation and survival in fructose-treated C. elegans. Given the evolutionary conservation of key pathways involved in glucose metabolism, this model provides a simple and reproducible platform to investigate mechanisms of glucose dysregulation and to screen compounds with potential metabolic or antidiabetic activity.
- 1 June 2026
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Open AccessTaurine reduces intracellular glucose accumulation in fructose-treated Caenorhabditis elegans
Regulation of glucose homeostasis is a central feature of antidiabetic drugs such as metformin. However, a subset of individuals exhibited limited therapeutic response, highlighting the need for complementary treatment strategies. Taurine, a semi-essential amino acid, has been reported to improve glycemic control in mammalian models, supporting its potential as an adjuvant therapy for metabolic disorders. In this study, we established a fructose-induced metabolic dysfunction model in Caenorhabditis elegans (C. elegans), characterized by increased intracellular glucose accumulation, and evaluated the effects of taurine. A metabolic dysfunction state was induced in L1-stage N2 Bristol worms by exposing them to 500 mM fructose for 48 h. Metformin (25, 50, and 100 µM) was initially used to establish an effective pharmacological control, and the optimal dose (50 µM) was subsequently employed as a positive control to assess the effects of taurine (10, 50, and 100 µM) under fructose-induced conditions. Fructose exposure significantly increased intracellular glucose levels. Metformin reduced intracellular glucose at all concentrations tested and improved survival at the lowest dose, without affecting morphological parameters. Taurine reduced intracellular glucose accumulation only at the highest concentration tested (100 µM), whereas lower concentrations selectively increased survival, indicating dose-dependent and functionally distinct effects on glucose regulation and organismal viability. These findings show that taurine modulates intracellular glucose accumulation and survival in fructose-treated C. elegans. Given the evolutionary conservation of key pathways involved in glucose metabolism, this model provides a simple and reproducible platform to investigate mechanisms of glucose dysregulation and to screen compounds with potential metabolic or antidiabetic activity.
- 9 November 2021
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 82 (1) , 39-49
6‐Shogaol improves behavior and memory in Wistar rats prenatally exposed to lipopolysaccharide
Objective: 6‐Shogaol, bioactive compound of Zingiber officinale Roscoe, has anti‐inflammatory, antioxidant, and neuroprotective properties. The objective of the present study was to verify the effect of 6‐shogaol on behavioral parameters in a preclinical model based on a maternal immune activation (MIA) by lipopolysaccharide (LPS).Methodology: Twelve pregnant Wistar rats received 100‐μg/kg LPS or saline solution on gestational day (GD) 9.5. Male offspring participated in the study and in the postnatal day (PND) 30 and 55 were supplemented with 6‐shogaol or saline solution, by gavage at a dose of 10 mg/kg/day, orally for 5 days. In the PND 35 and 60 was performed the behavioral tests: grooming, crossing, and rearing that evaluated repetitive movements, anxiety, and interest in the new, respectively, and the inhibitory avoidance test that evaluated short‐term (STM) and long‐term memory (LTM).Result: Prenatal exposure to LPS increased the grooming and crossing episodes at different ages and reduced rearing episodes in PND 37. Treatment with 6‐shogaol reversed these parameters. In the inhibitory avoidance test, an improvement of memory was identified with 6‐shogaol in the STM and LTM at both ages comparing training and test session of treated groups and between groups.Conclusion: Administration of 6‐shogaol reverses the stereotypy, exploratory behavior, and memory impairment in prenatal LPS‐exposed offspring, acting as a promising therapeutic component against brain disorders associated with the process of MIA.
- 9 November 2021
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 82 (1) , 39-49
6‐Shogaol improves behavior and memory in Wistar rats prenatally exposed to lipopolysaccharide
Objective: 6‐Shogaol, bioactive compound of Zingiber officinale Roscoe, has anti‐inflammatory, antioxidant, and neuroprotective properties. The objective of the present study was to verify the effect of 6‐shogaol on behavioral parameters in a preclinical model based on a maternal immune activation (MIA) by lipopolysaccharide (LPS).Methodology: Twelve pregnant Wistar rats received 100‐μg/kg LPS or saline solution on gestational day (GD) 9.5. Male offspring participated in the study and in the postnatal day (PND) 30 and 55 were supplemented with 6‐shogaol or saline solution, by gavage at a dose of 10 mg/kg/day, orally for 5 days. In the PND 35 and 60 was performed the behavioral tests: grooming, crossing, and rearing that evaluated repetitive movements, anxiety, and interest in the new, respectively, and the inhibitory avoidance test that evaluated short‐term (STM) and long‐term memory (LTM).Result: Prenatal exposure to LPS increased the grooming and crossing episodes at different ages and reduced rearing episodes in PND 37. Treatment with 6‐shogaol reversed these parameters. In the inhibitory avoidance test, an improvement of memory was identified with 6‐shogaol in the STM and LTM at both ages comparing training and test session of treated groups and between groups.Conclusion: Administration of 6‐shogaol reverses the stereotypy, exploratory behavior, and memory impairment in prenatal LPS‐exposed offspring, acting as a promising therapeutic component against brain disorders associated with the process of MIA.